EP2882496A4 - Treatment and diagnosis of melanoma - Google Patents
Treatment and diagnosis of melanomaInfo
- Publication number
- EP2882496A4 EP2882496A4 EP13829165.3A EP13829165A EP2882496A4 EP 2882496 A4 EP2882496 A4 EP 2882496A4 EP 13829165 A EP13829165 A EP 13829165A EP 2882496 A4 EP2882496 A4 EP 2882496A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- melanoma
- diagnosis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003745 diagnosis Methods 0.000 title 1
- 201000001441 melanoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Emergency Medicine (AREA)
- General Engineering & Computer Science (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19189895.6A EP3626309B1 (en) | 2012-08-13 | 2013-08-13 | Lxrbeta agonist for the treatment of cancer |
EP23155232.4A EP4218935A1 (en) | 2012-08-13 | 2013-08-13 | Lxrbeta agonist for the treatment of cancer |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261682339P | 2012-08-13 | 2012-08-13 | |
US201361784057P | 2013-03-14 | 2013-03-14 | |
PCT/US2013/054690 WO2014028461A2 (en) | 2012-08-13 | 2013-08-13 | Treatment and diagnosis of melanoma |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23155232.4A Division EP4218935A1 (en) | 2012-08-13 | 2013-08-13 | Lxrbeta agonist for the treatment of cancer |
EP19189895.6A Division EP3626309B1 (en) | 2012-08-13 | 2013-08-13 | Lxrbeta agonist for the treatment of cancer |
EP19189895.6A Division-Into EP3626309B1 (en) | 2012-08-13 | 2013-08-13 | Lxrbeta agonist for the treatment of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2882496A2 EP2882496A2 (en) | 2015-06-17 |
EP2882496A4 true EP2882496A4 (en) | 2016-07-06 |
EP2882496B1 EP2882496B1 (en) | 2019-10-09 |
Family
ID=50101591
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23155232.4A Pending EP4218935A1 (en) | 2012-08-13 | 2013-08-13 | Lxrbeta agonist for the treatment of cancer |
EP13829165.3A Active EP2882496B1 (en) | 2012-08-13 | 2013-08-13 | Treatment and diagnosis of melanoma |
EP19189895.6A Active EP3626309B1 (en) | 2012-08-13 | 2013-08-13 | Lxrbeta agonist for the treatment of cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23155232.4A Pending EP4218935A1 (en) | 2012-08-13 | 2013-08-13 | Lxrbeta agonist for the treatment of cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19189895.6A Active EP3626309B1 (en) | 2012-08-13 | 2013-08-13 | Lxrbeta agonist for the treatment of cancer |
Country Status (11)
Country | Link |
---|---|
US (8) | US9526710B2 (en) |
EP (3) | EP4218935A1 (en) |
JP (5) | JP6320382B2 (en) |
CN (3) | CN110037999B (en) |
AU (4) | AU2013302861A1 (en) |
CA (2) | CA3211094A1 (en) |
DK (1) | DK2882496T3 (en) |
ES (2) | ES2941477T3 (en) |
HK (1) | HK1212273A1 (en) |
HU (1) | HUE046292T2 (en) |
WO (1) | WO2014028461A2 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2626437A3 (en) | 2008-05-14 | 2013-12-11 | Dermtech International | Diagnosis of melanoma and solar lentigo by nucleic acid analysis |
RS57863B9 (en) | 2012-03-02 | 2019-10-31 | Ralexar Therapeutics Inc | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
EP4218935A1 (en) * | 2012-08-13 | 2023-08-02 | The Rockefeller University | Lxrbeta agonist for the treatment of cancer |
WO2015035027A1 (en) | 2013-09-04 | 2015-03-12 | Alexar Therapeutics, Inc. | Liver x receptor (lxr) modulators |
HUE051094T2 (en) | 2013-09-04 | 2021-03-01 | Ellora Therapeutics Inc | Liver x receptor (lxr) modulators |
EP3091970B1 (en) * | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
WO2016100619A2 (en) * | 2014-12-17 | 2016-06-23 | Rgenix, Inc. | Treatment and diagnosis of cancer |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
JP2018518992A (en) * | 2015-06-24 | 2018-07-19 | オックスフォード バイオダイナミックス リミテッド | Detection method using site of chromosomal interaction |
US20200046671A1 (en) * | 2015-06-29 | 2020-02-13 | Regents Of The University Of Minnesota | Apobec3b mutagenesis and immunotherapy |
WO2017004151A1 (en) | 2015-06-29 | 2017-01-05 | Regents Of The University Of Minnesota | Anti-apobec3 antibodies and methods of making and using |
EP3402477A4 (en) * | 2016-01-11 | 2019-08-21 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
WO2017142988A1 (en) * | 2016-02-18 | 2017-08-24 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating melanoma |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
WO2018013534A1 (en) * | 2016-07-11 | 2018-01-18 | Dana-Farber Cancer Institute, Inc. | Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents |
ES2928773T3 (en) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Protein kinase inhibitors to promote liver regeneration or reduce or prevent hepatocyte death |
CN117126069A (en) * | 2017-03-03 | 2023-11-28 | 因思博纳公司 | Formulations with improved stability |
CN106890315B (en) * | 2017-03-16 | 2019-09-06 | 北京热休生物技术有限公司 | APO-E albumen and its polypeptide are in treatment and the application in pre- anti-cancer |
MX2019013634A (en) * | 2017-05-16 | 2020-01-21 | Biomed Valley Discoveries Inc | Compositions and methods for treating cancer with atypical braf mutations. |
EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | Polymorphs and uses thereof |
EP3752645A4 (en) | 2018-02-14 | 2022-04-13 | Dermtech, Inc. | Novel gene classifiers and uses thereof in non-melanoma skin cancers |
MX2021006253A (en) * | 2018-11-28 | 2021-09-21 | Prevail Therapeutics Inc | Gene therapies for neurodegenerative disease. |
EP3931349A4 (en) * | 2019-02-28 | 2023-02-08 | The Rockefeller University | Apoe genotyping in cancer prognostics and treatment |
EP3948290A4 (en) | 2019-03-26 | 2023-08-09 | Dermtech, Inc. | Novel gene classifiers and uses thereof in skin cancers |
WO2020222858A1 (en) * | 2019-04-27 | 2020-11-05 | Ocugen, Inc. | Adeno-associated virus vector mediated gene therapy for ophthalmic diseases |
CN110218235B (en) * | 2019-05-09 | 2020-09-25 | 中山大学 | Compound, preparation method thereof and application of compound as fluorescent polarization probe in LXR beta ligand screening |
JP2022547554A (en) * | 2019-09-11 | 2022-11-14 | インスピルナ,インコーポレーテッド | Methods of treating cancer |
US20220339184A1 (en) * | 2019-09-27 | 2022-10-27 | The Rockefeller University | Compositions and methods to treat metastatic gastrointestinal cancer |
RU2716811C1 (en) * | 2019-11-14 | 2020-03-16 | федеральное государственное бюджетное образовательное учреждение высшего образования "Новгородский государственный университет имени Ярослава Мудрого" | Method for early diagnosis of surface-propagating melanomas |
MX2022007164A (en) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Metal salts and uses thereof. |
EP4081302A1 (en) | 2019-12-23 | 2022-11-02 | University Of Massachusetts | Oligonucleotides for tissue specific gene expression modulation |
EP4376953A1 (en) * | 2021-07-30 | 2024-06-05 | Alnylam Pharmaceuticals, Inc. | Peptide ligands for cns and ocular delivery of rnai compounds |
CN114276999A (en) * | 2022-03-03 | 2022-04-05 | 中日友好医院(中日友好临床医学研究所) | Melanoma cell strain and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002563A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
WO2010138598A2 (en) * | 2009-05-28 | 2010-12-02 | Exelixis, Inc. | Lxr modulators |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5324731A (en) | 1989-02-14 | 1994-06-28 | Amira, Inc. | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
US5676978A (en) | 1989-02-14 | 1997-10-14 | Amira, Inc. | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5215882A (en) | 1989-11-30 | 1993-06-01 | Ortho Diagnostic Systems, Inc. | Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
DE69621507T2 (en) | 1995-03-28 | 2003-01-09 | Japan Science And Technology Corp., Kawaguchi | Method for molecular indexing of genes using restriction enzymes |
US5843974A (en) * | 1995-06-06 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se |
US5958342A (en) | 1996-05-17 | 1999-09-28 | Incyte Pharmaceuticals, Inc. | Jet droplet device |
US6060240A (en) | 1996-12-13 | 2000-05-09 | Arcaris, Inc. | Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom |
US6090556A (en) | 1997-04-07 | 2000-07-18 | Japan Science & Technology Corporation | Method for quantitatively determining the expression of a gene |
US5994076A (en) | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
ES2276481T3 (en) | 1997-12-12 | 2007-06-16 | The University Of Western Ontario | PEPTIDO APOEP1.B NOVEDOSO, COMPOSITIONS AND ITS USES. |
US6004755A (en) | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6087112A (en) | 1998-12-30 | 2000-07-11 | Oligos Etc. Inc. | Arrays with modified oligonucleotide and polynucleotide compositions |
US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
US8257750B2 (en) | 1999-04-30 | 2012-09-04 | Kibow Biotech, Inc. | Calcium carbonate compositions for preventing or treating hyperphosphatemia |
AU2001280576A1 (en) | 2000-07-18 | 2002-01-30 | Uab Research Foundation | Tissue-specific self-inactivating gene therapy vector |
US20030027335A1 (en) | 2000-09-07 | 2003-02-06 | Ruley H. Earl | Genome engineering by cell-permeable DNA site-specific recombinases |
ATE283253T1 (en) | 2000-09-18 | 2004-12-15 | Glaxo Group Ltd | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES AS LXR AGONISTS |
AU2002219718A1 (en) | 2000-12-13 | 2002-06-24 | Sca Hygiene Products Zeist B.V. | Process for oxidising primary alcohols |
JP2003033179A (en) | 2001-07-05 | 2003-02-04 | Asahi Kasei Corp | Vector for reversible transduction of gene |
AU2003220558A1 (en) * | 2002-03-27 | 2004-06-03 | Smithkline Beecham Corporation | Amide compounds and methods of using the same |
WO2003082205A2 (en) | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Compounds and methods |
US7560586B2 (en) | 2002-03-27 | 2009-07-14 | Smithkline Beecham Corporation | Acid and ester compounds and methods of using the same |
DE60332948D1 (en) | 2002-07-19 | 2010-07-22 | Althea Technologies Inc | STRATEGIES FOR GENE EXPRESSION ANALYSIS |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
WO2004078939A2 (en) | 2003-03-03 | 2004-09-16 | University Of Massachusetts | REGULATION OF Mdm2 FUNCTION |
US20050130919A1 (en) | 2003-07-18 | 2005-06-16 | University Of Massachusetts | Regulatable promoters for synthesis of small hairpin RNA |
BRPI0415563A (en) | 2003-10-20 | 2007-01-02 | Nsgene As | method for treating parkinson's disease, use of a viral vector, viral expression vector, pharmaceutical composition, isolated host cell, packaging cell line, chimeric non-human mammal, implantable cell culture device, biocompatibly capsule, method for treatment of a nervous system disease, mammalian cell, and, method for producing neurturin or a functional equivalent thereof |
SV2005001973A (en) | 2003-12-12 | 2005-11-04 | Wyeth Corp | USEFUL KINOLINES IN THE TREATMENT OF CARDIOVASCULAR DISEASES REF. WYTH0090-504 (AM101500) |
FR2865736B1 (en) | 2004-02-02 | 2006-07-14 | Synt Em | INHIBITORS OF ANGIOGENESIS, COMPOSITIONS CONTAINING SAME AND USE THEREOF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH DEREGULATION OF ANGIOGENESIS |
WO2005112620A2 (en) | 2004-05-18 | 2005-12-01 | Massachusetts Institute Of Technology | A cre-lox based method for conditional rna interference |
BRPI0512707A (en) * | 2004-07-02 | 2008-04-01 | Sankyo Co | tissue factor production inhibitor |
AU2005272043B2 (en) | 2004-07-07 | 2010-07-29 | Merck Sharp & Dohme Corp. | Pyrazole amide derivatives, compositions containing such compounds and methods of use |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
AU2005291540B2 (en) | 2004-10-01 | 2008-06-19 | F. Hoffmann-La Roche Ag | Hexafluoroisopropanol substituted ether derivatives |
JP4644714B2 (en) | 2004-12-22 | 2011-03-02 | エフ.ホフマン−ラ ロシュ アーゲー | New cyclohexane derivatives |
SE0500056D0 (en) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 4 |
KR20070094963A (en) | 2005-01-10 | 2007-09-27 | 아스트라제네카 아베 | Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
SE0500055D0 (en) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
JP2008526842A (en) | 2005-01-10 | 2008-07-24 | アストラゼネカ アクチボラグ | Aniline derivatives of isothiazole-3 (2H) -thione 1,1-dioxide as liver X receptor modulators |
SE0500058D0 (en) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
RU2007131400A (en) | 2005-03-01 | 2009-04-10 | Вайет (Us) | COMPOUNDS OF CINNOLINE AND THEIR APPLICATION AS MODULATORS OF LIVER X-RECEPTORS |
US8318760B2 (en) | 2005-03-21 | 2012-11-27 | Merck Sharp & Dohme Corp. | Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use |
CN110668988A (en) | 2005-10-07 | 2020-01-10 | 埃克塞利希斯股份有限公司 | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
JP2009515904A (en) | 2005-11-14 | 2009-04-16 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Compounds and compositions as LXR modulators |
WO2007081335A1 (en) | 2006-01-12 | 2007-07-19 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
US20100279918A1 (en) | 2006-03-20 | 2010-11-04 | Burnham Institute For Medical Research | Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents |
WO2008011071A2 (en) * | 2006-07-19 | 2008-01-24 | The Regents Of The University Of California | Interactions of hedgehog and liver x receptor signaling pathways |
TW200825054A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
WO2008065754A1 (en) | 2006-11-30 | 2008-06-05 | Kowa Company, Ltd. | Substituted carbinol compound |
WO2008073825A1 (en) | 2006-12-08 | 2008-06-19 | Exelixis, Inc. | Lxr and fxr modulators |
JP2008179562A (en) | 2007-01-24 | 2008-08-07 | Kowa Co | Lxr agonist |
US8993628B2 (en) | 2007-02-23 | 2015-03-31 | City Of Hope | Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof |
CA2685002A1 (en) | 2007-05-18 | 2009-02-12 | Wyeth | Quinazoline compounds |
EP2170363B1 (en) | 2007-06-29 | 2018-08-08 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
CN101778831B (en) | 2007-08-13 | 2014-08-20 | 霍夫曼-拉罗奇有限公司 | Novel piperazine amide derivatives |
TW200922582A (en) | 2007-08-20 | 2009-06-01 | Organon Nv | N-benzyl, N'-arylcarbonylpiperazine derivatives |
US8039493B2 (en) | 2007-09-27 | 2011-10-18 | Hoffmann-La Roche Inc. | Biaryl sulfonamide derivatives |
ES2463665T3 (en) * | 2007-10-04 | 2014-05-28 | Stella Aps | Combination treatment for the treatment of hepatitis C virus infection |
DK2219672T3 (en) | 2007-11-09 | 2016-05-17 | Peregrine Pharmaceuticals Inc | The anti-VEGF antibody compositions and methods |
US8236753B2 (en) * | 2007-12-10 | 2012-08-07 | The Brigham And Women's Hospital, Inc. | RAP variants for drug delivery and methods of use thereof |
EP2235020A1 (en) | 2007-12-21 | 2010-10-06 | Wyeth LLC | Pyrazolo [1,5-a] pyrimidine compounds |
AU2008345688A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth Llc | Imidazo [1,2-b] pyridazine compounds as modulators of liver X receptors |
US20110034526A1 (en) | 2007-12-21 | 2011-02-10 | Wyeth Llc | Benzimidazole Compounds |
AU2008345681A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth Llc | Imidazo [1,2-a] pyridine compounds |
US7919509B2 (en) | 2008-02-29 | 2011-04-05 | Kowa Company, Ltd. | 2-oxochromene derivatives |
MX2010012579A (en) * | 2008-05-29 | 2010-12-20 | Squibb Bristol Myers Co | Methods for predicting patient response to modulation of the co-stimulatory pathway. |
WO2010002982A1 (en) * | 2008-07-01 | 2010-01-07 | Cognosci, Inc. | Methods of treating cancer with apoe peptides |
JP6087503B2 (en) | 2008-09-26 | 2017-03-08 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses thereof |
US20120156216A1 (en) * | 2009-03-02 | 2012-06-21 | Youngman Oh | Methods and Compositions for Treatment of Tumor Metastasis |
WO2011115892A1 (en) * | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
WO2011130426A2 (en) * | 2010-04-13 | 2011-10-20 | New York University | Compositions and methods for treatment of melanoma |
US20130090258A1 (en) | 2010-06-16 | 2013-04-11 | National University Corporation Hamamatsu University School Of Medicines | Method for detecting colorectal tumor |
EP2474617A1 (en) * | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
AR088728A1 (en) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | LXR MODULATORS AS IMIDAZOL PRODROGA |
AU2013201121A1 (en) * | 2011-09-20 | 2013-04-04 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
EP4218935A1 (en) * | 2012-08-13 | 2023-08-02 | The Rockefeller University | Lxrbeta agonist for the treatment of cancer |
-
2013
- 2013-08-13 EP EP23155232.4A patent/EP4218935A1/en active Pending
- 2013-08-13 ES ES19189895T patent/ES2941477T3/en active Active
- 2013-08-13 CA CA3211094A patent/CA3211094A1/en active Pending
- 2013-08-13 WO PCT/US2013/054690 patent/WO2014028461A2/en active Application Filing
- 2013-08-13 AU AU2013302861A patent/AU2013302861A1/en not_active Abandoned
- 2013-08-13 DK DK13829165T patent/DK2882496T3/en active
- 2013-08-13 EP EP13829165.3A patent/EP2882496B1/en active Active
- 2013-08-13 CN CN201811502066.5A patent/CN110037999B/en active Active
- 2013-08-13 HU HUE13829165A patent/HUE046292T2/en unknown
- 2013-08-13 CN CN202211715800.2A patent/CN116271053A/en active Pending
- 2013-08-13 JP JP2015527533A patent/JP6320382B2/en active Active
- 2013-08-13 EP EP19189895.6A patent/EP3626309B1/en active Active
- 2013-08-13 CN CN201380053478.4A patent/CN104780976B/en active Active
- 2013-08-13 CA CA2882292A patent/CA2882292C/en active Active
- 2013-08-13 ES ES13829165T patent/ES2765573T3/en active Active
-
2014
- 2014-09-15 US US14/486,477 patent/US9526710B2/en active Active
- 2014-09-15 US US14/486,466 patent/US9399028B2/en active Active
-
2016
- 2016-01-14 HK HK16100415.9A patent/HK1212273A1/en unknown
- 2016-08-04 US US15/228,643 patent/US9707195B2/en active Active
-
2017
- 2017-07-14 US US15/650,480 patent/US9962348B2/en active Active
-
2018
- 2018-01-26 US US15/881,231 patent/US10543183B2/en active Active
- 2018-02-14 JP JP2018023820A patent/JP6523502B2/en active Active
- 2018-09-07 AU AU2018226488A patent/AU2018226488B2/en active Active
-
2019
- 2019-04-25 JP JP2019083874A patent/JP7005551B2/en active Active
- 2019-12-23 US US16/725,493 patent/US10945978B2/en active Active
-
2020
- 2020-01-31 AU AU2020200715A patent/AU2020200715B2/en active Active
-
2021
- 2021-03-15 US US17/201,493 patent/US11865094B2/en active Active
- 2021-06-24 JP JP2021105207A patent/JP7472080B2/en active Active
-
2022
- 2022-08-12 AU AU2022215282A patent/AU2022215282A1/en active Pending
-
2023
- 2023-12-28 JP JP2023223727A patent/JP2024041827A/en active Pending
-
2024
- 2024-01-03 US US18/403,027 patent/US20240252458A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002563A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
WO2010138598A2 (en) * | 2009-05-28 | 2010-12-02 | Exelixis, Inc. | Lxr modulators |
Non-Patent Citations (3)
Title |
---|
NORA PENCHEVA ET AL: "Control of metastatic progression by microRNA regulatory networks", NATURE CELL BIOLOGY, vol. 15, no. 6, 3 June 2013 (2013-06-03), GB, pages 546 - 554, XP055248968, ISSN: 1465-7392, DOI: 10.1038/ncb2769 * |
PENCHEVA NORA ET AL: "Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation", CELL, CELL PRESS, US, vol. 156, no. 5, 27 February 2014 (2014-02-27), pages 986 - 1001, XP028667658, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2014.01.038 * |
WENJUN ZHANG ET AL: "Liver X receptor activation induces apoptosis of melanoma cell through caspase pathway", CANCER CELL INTERNATIONAL, BIOMED CENTRAL, LONDON, GB, vol. 14, no. 1, 25 February 2014 (2014-02-25), pages 16, XP021178543, ISSN: 1475-2867, DOI: 10.1186/1475-2867-14-16 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212273A1 (en) | Treatment and diagnosis of melanoma | |
HRP20181628T1 (en) | Compounds and their methods of use | |
HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
ZA201502503B (en) | Hppd variants and methods of use | |
EP2968397A4 (en) | Diagnosis and treatment of fibrosis | |
EP2890808A4 (en) | Diagnosis and treatment of autism spectrum disorder | |
EP2912178A4 (en) | Super-enhancers and methods of use thereof | |
EP2890815A4 (en) | Methods for diagnosis and treatment of cancer | |
EP2874647A4 (en) | Method of diagnosis and treatment | |
EP2901151A4 (en) | Diagnostic devices and methods | |
EP2893030A4 (en) | Diagnosis and treatment of invasive aspergillosis | |
EP2814409A4 (en) | Reflectance-facilitated ultrasound treatment and monitoring | |
EP2867239A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | |
HK1215000A1 (en) | Treatment and diagnosis of colon cancer | |
HK1201045A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP2852397A4 (en) | Huwentoxin-iv variants and methods of use | |
ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
EP2670438A4 (en) | Selection and treatment of subjects | |
EP2922402A4 (en) | Diagnosis and treatment of sma and smn deficiency | |
EP2906576A4 (en) | Glycosphingolipids and methods of use thereof | |
EP2800568A4 (en) | Compositions, methods of use, and methods of treatment | |
ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
EP2924046A4 (en) | Novel complex and use of same | |
GB201208505D0 (en) | Treatment of skin condition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150212 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/136 20060101ALI20160212BHEP Ipc: C12N 15/113 20100101ALI20160212BHEP Ipc: A61K 31/4155 20060101ALI20160212BHEP Ipc: A61P 35/04 20060101AFI20160212BHEP Ipc: A61K 31/416 20060101ALI20160212BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20160608 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/4155 20060101ALI20160602BHEP Ipc: C12N 15/113 20100101ALI20160602BHEP Ipc: A61K 31/416 20060101ALI20160602BHEP Ipc: A61K 31/136 20060101ALI20160602BHEP Ipc: A61P 35/04 20060101AFI20160602BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180115 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20190410 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013061574 Country of ref document: DE Ref country code: CH Ref legal event code: NV Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20191107 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1188092 Country of ref document: AT Kind code of ref document: T Effective date: 20191115 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20191009 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E046292 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1188092 Country of ref document: AT Kind code of ref document: T Effective date: 20191009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200109 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200110 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200210 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2765573 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200609 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013061574 Country of ref document: DE |
|
PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200209 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
26N | No opposition filed |
Effective date: 20200710 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191009 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230517 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230826 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230720 Year of fee payment: 11 Ref country code: NO Payment date: 20230829 Year of fee payment: 11 Ref country code: MC Payment date: 20230720 Year of fee payment: 11 Ref country code: IT Payment date: 20230822 Year of fee payment: 11 Ref country code: IE Payment date: 20230828 Year of fee payment: 11 Ref country code: GB Payment date: 20230828 Year of fee payment: 11 Ref country code: FI Payment date: 20230825 Year of fee payment: 11 Ref country code: ES Payment date: 20230901 Year of fee payment: 11 Ref country code: CH Payment date: 20230902 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230827 Year of fee payment: 11 Ref country code: HU Payment date: 20230725 Year of fee payment: 11 Ref country code: FR Payment date: 20230825 Year of fee payment: 11 Ref country code: DK Payment date: 20230829 Year of fee payment: 11 Ref country code: DE Payment date: 20230829 Year of fee payment: 11 Ref country code: BE Payment date: 20230828 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MT Payment date: 20230718 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20240827 Year of fee payment: 12 |